The Revolutionizing Atopic Dermatitis conference, set to begin on April 29 in Washington, DC, promises to offer symposia on emerging therapies and new insights into treating atopic dermatitis (AD).
The 5th annual Revolutionizing Atopic Dermatitis (RAD) conference will take place in Washington, DC, from April 29 to May 1, 2023. The conference, which will be held in person, promises to offer symposia on emerging therapies and new insights into treating AD as well as competitions and games to keep spirits up throughout the weekend.
The first full day of RAD will take place on Sunday, when the Battle of the 2 Titans will open the agenda. The event will feature Andrew Blauvet, MD, and Jonathan Silverberg, MD, PhD, who will compete against each other to determine which cases are eligible for systemic treatment of AD.
“This is the second installment of the Battle of the Titans. It’s been a really incredible fun and educational intellectual boxing match,” Silverberg said in an interview with The American Journal of Managed Care®. “Trying to address some different approaches that we can use in clinical practice and different considerations to make sure that we [explore] how we better do this in clinical practice…so it’s going to be a really fun session in order to address that.”
Silverberg will also host Atopic Dermatitis Games at the end of the first day of the conference, during which he and Diamant Thaçi, MD, will take part in The Great Debate – Rematch, then a “JeopArDy” game will be played with the remaining panelists. The event gives attendees a chance for some levity during amid the exciting research being presented throughout the remainder of the conference.
Symposia and late-breaking research will be covered on April 30 and May 1. April 30 features a mini-symposium on new insights into AD. Panelists Anna de Benedetto, MD; Lawrence Eichenfield, MD; Thaci, and Silverberg will talk about new discoveries in AD, insights into topical phosphodiesterase-4 and Janus kinase (JAK) inhibitors, insights into biologics, and insights into oral JAK inhibitors, respectively.
Melinda Gooderham, MSc, MD, FRCPC, will be moderating a separate panel on May 1 covering emerging therapies in AD. Gooderman will be speaking on therapies coming in 2023, whereas her fellow panelist David Rosmarin, MD, will be covering therapies that will be coming in the years to follow.
A panel on reducing racial disparities will conclude all sessions on Monday afternoon. Andrew Alexis, MD, will discuss disparities in the care of AD in United States; Candrice Heath, MD, will be addressing racism in medicine generally; and Adam Friedman, MD, will close out the panel by discussing how teledermatology could reduce disparities in care for AD.
Late-breaking research will be presented throughout the conference. Studies on the effectiveness of lebrikizumab, dupilumab, and ruxolitinib are among the research that will be presented by the lead authors of each study.
The closing remarks for RAD, delivered by Silverberg, will come at 4:00 PM on Monday, May 1, to close out the conference.